780.5 USD
-4.47 (-0.57%)
780.5 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 80% to REGN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 808.25. This target is 3.56% above the current price.
REGN was analyzed by 36 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about REGN.
In the previous month the buy percentage consensus was at a similar level.
REGN was analyzed by 36 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-12 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-12-10 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-12-04 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-12-04 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-12-03 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2025-11-24 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2025-11-24 | HSBC | Initiate | Buy |
| 2025-11-20 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-07 | UBS | Maintains | Neutral -> Neutral |
| 2025-10-29 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-10-29 | Guggenheim | Maintains | Buy -> Buy |
| 2025-10-29 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-10-29 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-29 | B of A Securities | Maintains | Underperform -> Underperform |
| 2025-10-29 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-23 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-10-14 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-10-13 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-10 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-08-27 | Bernstein | Maintains | Outperform -> Outperform |
| 2025-08-27 | Jefferies | Maintains | Buy -> Buy |
| 2025-08-11 | Truist Securities | Maintains | Buy -> Buy |
| 2025-08-04 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-04 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-08-04 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-08-04 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-07-23 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-07-11 | UBS | Maintains | Neutral -> Neutral |
| 2025-07-10 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-06-09 | JP Morgan | Maintains | Overweight -> Overweight |
REGENERON PHARMACEUTICALS / REGN FAQ
Can you provide the average price target for REGENERON PHARMACEUTICALS stock?
36 analysts have analysed REGN and the average price target is 808.25 USD. This implies a price increase of 3.56% is expected in the next year compared to the current price of 780.5.
Can you provide the consensus rating for REGENERON PHARMACEUTICALS stock?
The consensus rating for REGENERON PHARMACEUTICALS (REGN) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for REGN stock?
The number of analysts covering REGENERON PHARMACEUTICALS (REGN) is 36.